FDA authorizes remdesivir for certain non-hospitalized patients, new at-home test for COVID-19

Jan 24, 2022 - 02:10 PM
FDA product update

The Food and Drug Administration Friday expanded the approved uses for Vekury (remdesivir) to include non-hospitalized patients aged 12 and older who test positive for SARS-CoV-2, weigh at least 88 pounds and are at high risk of progressing to severe COVID-19. The agency also authorized emergency use of the drug for high-risk, non-hospitalized pediatric patients who weigh less than 88 but more than 8 pounds, including patients under age 12. The drug previously was limited to hospitalized patients. The expanded uses are based on results from a clinical trial that showed the drug reduced hospitalizations in high-risk, non-hospitalized patients. For more information, see the updated provider and patient fact sheets.

In other news, the FDA last week issued an emergency use authorization for another over-the-counter COVID-19 test. It said the MaximBio ClearDetect COVID-19 Antigen Home Test delivers results in 15 minutes.

 

Related News Articles

Headline
CDC updates masking guidelines for health care facilities
The Centers for Disease Control and Prevention this week recommended health care facilities use a risk-based assessment, stakeholder input and local metrics to…
Headline
CMS bulletin reviews end dates for certain Medicaid, CHIP COVID-19 flexibilities
A new Centers for Medicare & Medicaid Services bulletin reviews the anticipated end dates for certain COVID-19-related Medicaid and Children’s Health…
Headline
FDA: Don’t use certain SD Biosensor COVID-19 tests  
Consumers and health care providers should not use certain SD Biosensor Pilot COVID-19 At-Home Tests distributed by Roche Diagnostics due to bacterial…
Headline
Newest AHA COVID-19 vaccination digital toolkit seeks to beat the summertime blues
Summertime is right around the corner and AHA’s new social media toolkit promotes COVID-19 vaccination and boosters as a means for keeping kids active and…
Headline
FDA authorizes 4th Pfizer COVID-19 bivalent dose for certain children under 5
The Food and Drug Administration April 28 authorized a fourth Pfizer COVID-19 bivalent vaccine dose at least one month after the third dose for certain…
Headline
CDC: Monovalent vaccination was 76% effective at preventing mechanical ventilation, death in hospitalized COVID-19 patients during omicron
In a study of adults hospitalized between February 2022 and February 2023, when the omicron variant predominated, monovalent mRNA vaccination was 76%…